Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Sale!
iBET-BD1 dihydrochloride (GSK778)
AOB11459
CAS: 2451862-42-1 (free base)
Chemical Name: GSK778 2HCl; 4-(2-(Methoxymethyl)-1-((R)-1-phenylethyl)-8-(((S)-pyrrolidin-3-yl)methoxy)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole dihydrochloride
976 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $101.15 | Total: $505.75 |
| 1 | 10 | $85.68 | Total: $856.80 |
| 1 | 25 | $72.59 | Total: $1,814.75 |
| 1 | 50 | $61.88 | Total: $3,094.00 |
| 1 | 100 | $53.55 | Total: $5,355.00 |
Overview
Novel potent and selective BD1 inhibior (IC50: BRD2 BD1: 75nM; BRD3 BD1 41nM; BRD4 BD1 41nM)
Chemical Properties
| Molecular Formula | C30H35Cl2N5O3 |
| Molecular Weight | 584.5 |
| CAS Numbers | 2451862-42-1 (free base) |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | 4-(2-(Methoxymethyl)-1-((R)-1-phenylethyl)-8-(((S)-pyrrolidin-3-yl)methoxy)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole dihydrochloride |
| SMILES Code | CC1=NOC(C)=C1C2=C(OC[C@@H]3CNCC3)C=C4C5=C(N=C(COC)N5[C@H](C)C6=CC=CC=C6)C=NC4=C2 |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
Synonyms
GSK778 2HCl, iBETBD1
References
1) Omer Gilan et al., Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation, Science 24 Apr 2020: